JP2018528266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528266A5 JP2018528266A5 JP2018528109A JP2018528109A JP2018528266A5 JP 2018528266 A5 JP2018528266 A5 JP 2018528266A5 JP 2018528109 A JP2018528109 A JP 2018528109A JP 2018528109 A JP2018528109 A JP 2018528109A JP 2018528266 A5 JP2018528266 A5 JP 2018528266A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- honokiol
- magnolol
- disorder
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 88
- 238000009472 formulation Methods 0.000 claims description 80
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims description 54
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims description 18
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims description 18
- 229940119224 salmon oil Drugs 0.000 claims description 18
- 239000011719 vitamin A Substances 0.000 claims description 12
- 235000019155 vitamin A Nutrition 0.000 claims description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 11
- 229940045997 vitamin a Drugs 0.000 claims description 11
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 10
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000004006 olive oil Substances 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 8
- 239000006186 oral dosage form Substances 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 5
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 241001673966 Magnolia officinalis Species 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 4
- 235000003248 hydroxytyrosol Nutrition 0.000 claims description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000017164 Chronobiology disease Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010029333 Neurosis Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000013200 Stress disease Diseases 0.000 claims description 2
- 208000003028 Stuttering Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 230000037328 acute stress Effects 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 230000002996 emotional effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015238 neurotic disease Diseases 0.000 claims description 2
- 208000019899 phobic disease Diseases 0.000 claims description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000027765 speech disease Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 230000000142 dyskinetic effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2534/DEL/2015 | 2015-08-17 | ||
| IN2534DE2015 | 2015-08-17 | ||
| PCT/IN2016/050021 WO2017029683A1 (en) | 2015-08-17 | 2016-01-18 | Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528266A JP2018528266A (ja) | 2018-09-27 |
| JP2018528266A5 true JP2018528266A5 (enExample) | 2019-02-21 |
| JP6663993B2 JP6663993B2 (ja) | 2020-03-13 |
Family
ID=58051448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528109A Expired - Fee Related JP6663993B2 (ja) | 2015-08-17 | 2016-01-18 | 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10328090B2 (enExample) |
| EP (1) | EP3337487B1 (enExample) |
| JP (1) | JP6663993B2 (enExample) |
| KR (1) | KR20180050331A (enExample) |
| AU (2) | AU2016308080A1 (enExample) |
| CA (1) | CA2995834A1 (enExample) |
| DK (1) | DK3337487T3 (enExample) |
| ES (1) | ES2873601T3 (enExample) |
| HU (1) | HUE054161T2 (enExample) |
| PL (1) | PL3337487T3 (enExample) |
| PT (1) | PT3337487T (enExample) |
| WO (1) | WO2017029683A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928250T3 (es) | 2018-03-21 | 2022-11-16 | Realtime Robotics Inc | Planificación del movimiento de un robot para diversos entornos y tareas y mejora del funcionamiento del mismo |
| WO2020138974A1 (ko) * | 2018-12-28 | 2020-07-02 | 충북대학교 산학협력단 | 일본 목련 추출물을 유효성분으로 함유하는 불안장애의 예방 또는 치료용 약학적 조성물 |
| WO2020154712A1 (en) * | 2019-01-25 | 2020-07-30 | Flaask, Llc | Compositions and methods for improving quality of life in patients with autism spectrum disorder |
| CN110585140A (zh) * | 2019-07-08 | 2019-12-20 | 苏州海特比奥生物技术有限公司 | 一种和厚朴酚纳米聚合物胶束冻干制剂及其制备方法 |
| WO2023283108A1 (en) * | 2021-07-05 | 2023-01-12 | Celesta Company LLC | Composition for promoting restful sleep and methods of making and using the same |
| WO2025136962A1 (en) * | 2023-12-19 | 2025-06-26 | Rebalance Health, Inc. | Compositions for reducing hot flashes and symptoms associated with anxiety and formulations thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582735B2 (en) | 2000-12-15 | 2003-06-24 | Npi, Llc. | Compositions and methods of use for extracts of magnoliaceae plants |
| CN1723011A (zh) | 2002-06-25 | 2006-01-18 | Wm·雷格利Jr·公司 | 含有厚朴提取物的口气清新和口腔清洁产品 |
| US7632525B2 (en) | 2002-06-25 | 2009-12-15 | Wm. Wrigley Jr. Company | Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents |
| RU2396941C2 (ru) | 2005-12-02 | 2010-08-20 | Джи Ай Си ИННОВАТИОНЗ КОМПАНИ | Наполнители с экстрактом коры магнолии для ухода за полостью рта |
| CN101321560B (zh) | 2005-12-02 | 2012-10-31 | Gic创新公司 | 具有快速释放的厚朴提取物的咀嚼性组合物 |
| US7470442B2 (en) | 2005-12-02 | 2008-12-30 | Gic Innovations Company | Confectionary compositions with magnolia bark extract |
| KR101527829B1 (ko) | 2007-04-19 | 2015-06-12 | 마리 케이 인코포레이티드 | 마그놀리아 추출물 함유 조성물 |
| WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
| DE102010015791A1 (de) * | 2010-04-20 | 2011-10-20 | Beiersdorf Ag | Wirkstoffkombinationen aus Magnolienrindenextrakt und polyethoxylierten Verbindungen |
| DE102010015792A1 (de) * | 2010-04-20 | 2011-10-20 | Beiersdorf Ag | Wirkstoffkombinationen aus Magnolienrindenextrakt und oberflächenaktiven Agentien |
| WO2012030208A1 (en) * | 2010-09-03 | 2012-03-08 | N.V. Nutricia | Method and preparation for the treatment or prevention of anxiety or neurogenesis |
| FR2970294B1 (fr) * | 2011-01-11 | 2012-12-28 | Peugeot Citroen Automobiles Sa | Ligne d'echappement pour un moteur a combustion interne |
| IE20110008A1 (en) | 2011-01-12 | 2012-08-01 | Patrick Thomas Prendergast | Compositions for alleviating:- stress, anxiety, depression and aiding with weight loss |
| WO2013043151A1 (en) * | 2011-09-19 | 2013-03-28 | Framroze Bomi P | Edible oil with a high concentration of poly-unsaturated fatty acids |
| CA2849294C (en) * | 2011-09-20 | 2023-03-21 | Vivaquant Llc | Physiological signal denoising |
-
2016
- 2016-01-18 ES ES16836765T patent/ES2873601T3/es active Active
- 2016-01-18 US US15/319,887 patent/US10328090B2/en active Active
- 2016-01-18 AU AU2016308080A patent/AU2016308080A1/en not_active Abandoned
- 2016-01-18 WO PCT/IN2016/050021 patent/WO2017029683A1/en not_active Ceased
- 2016-01-18 KR KR1020187007412A patent/KR20180050331A/ko not_active Ceased
- 2016-01-18 EP EP16836765.4A patent/EP3337487B1/en active Active
- 2016-01-18 CA CA2995834A patent/CA2995834A1/en not_active Abandoned
- 2016-01-18 PT PT168367654T patent/PT3337487T/pt unknown
- 2016-01-18 HU HUE16836765A patent/HUE054161T2/hu unknown
- 2016-01-18 DK DK16836765.4T patent/DK3337487T3/da active
- 2016-01-18 JP JP2018528109A patent/JP6663993B2/ja not_active Expired - Fee Related
- 2016-01-18 PL PL16836765T patent/PL3337487T3/pl unknown
-
2022
- 2022-02-24 AU AU2022201271A patent/AU2022201271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528266A5 (enExample) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| JP2015512418A5 (enExample) | ||
| AR081427A1 (es) | Metodo para preparar anticuerpos con propiedades mejoradas | |
| GB2462228A (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| NZ757815A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| CR20180289A (es) | DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS (Divisional 2013-0224) | |
| JP2016510316A5 (enExample) | ||
| JP2013523769A5 (enExample) | ||
| JP2016530291A5 (enExample) | ||
| EP4328218A3 (de) | Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat | |
| JP2015193582A5 (enExample) | ||
| JP2015131825A5 (enExample) | ||
| TN2016000250A1 (en) | Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists. | |
| MX2021006985A (es) | Metodos para el tratamiento de la depresión. | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| JP2018521007A5 (enExample) | ||
| UY35338A (es) | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| JP2014513130A5 (enExample) | ||
| CN104758226A (zh) | 一种天然环保护甲油 | |
| EA201500579A1 (ru) | Комбинированная терапия с использованием воласертиба | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| WO2005123651A8 (fr) | L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation |